Plain-English translation of NCT07371611 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called sintilimab combined with chemotherapy to treat advanced mouth cancer (oral squamous cell carcinoma). The treatment is given before surgery to shrink the tumor, then surgery is performed, and afterward treatment continues based on how well the tumor responded. Researchers believe this approach may help prevent the cancer from coming back compared to surgery alone with standard follow-up care.
Many patients with advanced mouth cancer still face a high risk of the cancer returning or spreading even after surgery and radiation therapy. Recent research shows that immunotherapy medications can be effective for head and neck cancers, and combining this new approach before and after surgery may offer better long-term survival than current standard treatments.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the new immunotherapy medication sintilimab combined with chemotherapy for several weeks before your surgery. After surgery, your doctor will examine the tumor tissue to see how well the treatment worked. If the tumor responded well, you'll receive the medication alone for at least six more cycles; if it responded less well, you may receive radiation therapy or chemoradiation followed by the medication. Throughout the trial, you'll have regular clinic visits, blood tests, and scans to monitor how you're doing and watch for side effects.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China